| | NCCN Drugs & Biologics CompendiumNCCN Breast Cancer Panel MembersThese chapters of the NCCN Drugs & Biologics Compendium™ were developed directly from the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These guidelines were developed by the following NCCN Breast Cancer Panel Members. Robert W. Carlson, MD/Chair* Stanford Comprehensive Cancer Center
D. Craig Allred, MD Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Benjamin O. Anderson, MD Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Harold J. Burstein, MD, PhD Dana-Farber/Brigham and Women's Cancer Center/Massachusetts General Hospital Cancer Center
W. Bradford Carter, MD H. Lee Moffitt Cancer Center & Research Institute
Stephen B. Edge, MD Roswell Park Cancer Institute
William B. Farrar, MD Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University
Lori J. Goldstein, MD Fox Chase Cancer Center
William J. Gradishar, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University
| Daniel F. Hayes, MD University of Michigan Comprehensive Cancer Center
Clifford A. Hudis, MD Memorial Sloan-Kettering Cancer Center
Mohammad Jahanzeb, MD* St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
Krystyna Kiel, MD* Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Britt-Marie Ljung, MD UCSF Helen Diller Family Comprehensive Cancer Center
Lawrence B. Marks, MD* Duke Comprehensive Cancer Center
Beryl McCormick, MD* Memorial Sloan-Kettering Cancer Center
Lisle M. Nabell, MD University of Alabama at Birmingham Comprehensive Cancer Center
Lori J. Pierce, MD* University of Michigan Comprehensive Cancer Center
| Elizabeth C. Reed, MD UNMC Eppley Cancer Center at The Nebraska Medical Center
Mary Lou Smith, JD, MBA Consultant
George Somlo, MD City of Hope
Richard L. Theriault, DO, MBA The University of Texas M. D. Anderson Cancer Center
Neal S. Topham, MD* Fox Chase Cancer Center
John H. Ward, MD* Huntsman Cancer Institute at the University of Utah
Eric P. Winer, MD Dana-Farber/Brigham and Women's Cancer Center/Massachusetts General Hospital Cancer Center
Antonio C. Wolff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
*Writing Committee Member Disclosures for the NCCN Breast Cancer Guidelines PanelAt the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Members of the panel indicated that they have received support from the following: Abbott Laboratories, American Bioscience, American Cancer Society, Amgen, AstraZeneca, Avon, Bayer, Boehringer Ingelheim Worldwide, Breast Cancer Research Foundation, Bristol-Myers Squibb, CALGB Foundation, Celgene, Dendreon, Department of Defense, Eisai, Eli Lilly, Ethicon Endo-Surgery, G.E. Healthcare, Genentech, Genomic Health, GlaxoSmithKline, Glaxo Wellcome, GPC Biotech AG, F. Hoffman-La Roche AG, Immunicon, Inc., Kosan Biosciences, Lance Armstrong Foundation, MedImmune, Millennium, Myriad, NCI, NIH, Novartis, Oncotech, Ortho Biotech, OSI, Pfizer, Precision Therapeutics, Inc., Rhone Pouloc Roher, Inc., Roche, Sanofi-Aventis, Susan G. Komen For The Cure, Taiho Pharmaceuticals, Varian Medical Systems, Veridex, and Wyeth. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member. | |